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oes Angiographic Response
o Wiring of Totally Occluded
essels Predict Outcomes in
T-Segment Elevation
yocardial Infarction?*
ohn A. Ambrose, MD, Cyrus F. Buhari, DO, MS
resno, California
bservation has frequently been the foundation for some of
he most important research in medicine. New findings
ased on properly designed studies with well-established
tatistical methods can influence patient care. When an
bservational study reports a new finding from a properly
esigned trial, there are at least 3 fundamental questions
hat should be asked to assess its significance: 1) What is its
echanism? 2) What is the relationship to the end point
i.e., cause and effect or just an association)? 3) Are the
ndings relevant?
See page 51
In some situations, the answers are rather obvious. For
xample, thrombolytic therapy or primary percutaneous
oronary intervention (PCI) for ST-segment elevation myo-
ardial infarction (STEMI) can open occluded coronary
rteries, limit infarct size, and significantly decrease mortal-
ty (1). In other instances, the answers can be less apparent.
atients with an elevated C-reactive protein in most studies
re at increased risk for adverse events on follow-up inde-
endent of conventional risk. Is this an association (i.e., a
arker of inflammation or of atherosclerotic burden) or
ould there be a casual relationship secondary to a direct
ffect of the molecule (2)?
In this issue of JACC: Cardiovascular Interventions, Val-
imigli et al. (3) report on a pooled analysis from 2
lycoprotein inhibitor trials comparing tirofiban to abcix-
mab for primary PCI in STEMI. The second, and larger of
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Division of Cardiology, Department of Medicine, University of Califor-a
ia, San Francisco–Fresno, Fresno, California. The authors have reported that they
ave no relationships to disclose.he 2 trials, the MULTISTRATEGY (Multicenter Evalu-
tion of single High-Dose Bolus Tirofiban Versus Abcix-
mab With Sirolimus-Eluting Stent or Bare-Metal Stent in
cute Myocardial Infarction Study), also had a second
andomization comparing drug-eluting to bare-metal stent-
ng (4). Persistent TIMI (Thrombolysis In Myocardial
nfarction) flow grade 0 after wire insertion (AWI) was
ound to be a predictor of 30-day and 1-year mortality in
atients who otherwise had a successful primary PCI (3). In
multivariate analysis correcting for several potential con-
ounders, there was a 2- to 3-fold increase in mortality
ssociated with persistent TIMI flow grade 0 AWI (an
bsolute 3.8% to 5.8% increase in mortality) despite 89%
chieving TIMI flow grade 3 following PCI (an indepen-
ent core laboratory adjudicated all angiograms). TIMI flow
rade 0 AWI was a common phenomenon present in 266
49%) of the 540 individuals who presented with baseline
IMI flow grade 0. The majority but not all of these
atients were treated appropriately at discharge with class I
edications.
In an attempt to determine the significance of this finding
f persistent TIMI flow grade 0 AWI, the first question that
omes to mind is why does an occluded coronary artery
ollowing acute STEMI open after wire manipulation? A
ikely answer would be that in these cases, the thrombus
urden is not that large and wire manipulation causes a
mall amount of thrombus to dislodge, embolize distally,
nd allow for some antegrade flow distally. Fresh thrombus
s friable and is platelet-fibrin rich. Acutely, it may not be
rmly attached to the vessel wall substrate (5). Alternatively,
he wire may puncture a hole and merely create a channel
ithin a more organized thrombus without necessarily
eading to distal embolization. Studies of PCI using distal
rotection, however, commonly find plaque or thrombus in
he filter device (6,7). In the EMERALD (Enhanced
yocardial Efficacy and Removal by Aspiration of Liber-
ted Debris) and PROMISE (Protection Devices in PCI-
reatment of Myocardial Infarction for Salvage of Endan-
ered Myocardium Study) trials of distal protection in
TEMI, roughly 30% to 70% of patients had either plaque
nd/or thrombus debris retrieved in the filter device (6,7).
emporally, the timing of embolization (wire placement
nd/or balloon stent inflation) cannot be ascertained in
hese studies given the fact that the protection device was
nly removed after the procedure was finished. However, it
as been shown that slow distal flow is most likely to occur
uring balloon/stent deployment particularly if the balloon/
rtery ratio is1.0 (8,9). In addition, creatine kinase release
ollowing PCI in saphenous vein grafts is more likely to
ccur when the stent/artery (vein graft) ratio is 1.2 (10).
ne may also consider that the wire relieves vasospasm as
nother potential mechanism for partial distal flow although
necdotally, this appears unlikely as the reverse is usually the
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64ase. Vasospasm is a common phenomenon caused by wire
anipulation.
Concerning the 3 questions initially proposed the last is
asiest to answer in this study. A novel finding that
dentifies those at higher risk of mortality after primary PCI
or STEMI is potentially very relevant particularly if there
re maneuvers that might reverse the adverse outcome. The
ther questions are not as easy to resolve. If the mechanism
f TIMI flow grade 0 AWI is a larger thrombus burden that
revents the vessel from opening following wire placement,
hen embolization during balloon or stent inflation could be
likely scenario leading to larger infarctions that increase
ardiovascular mortality. Here, there could be a cause/effect
elationship of TIMI flow grade 0 AWI to increased
ortality. The fact that patients with persistent TIMI flow
rade 0 AWI in comparison with those without persistent
IMI flow grade 0 had significantly less ST-segment
esolution, lower left ventricular ejection fractions at dis-
harge, as well as a lower incidence of TIMI flow grade 3
fter the procedure could support this hypothesis. Further-
ore, if indeed this was the mechanism, then targeting this
roup with specific therapeutic maneuvers before stent
eployment could potentially improve outcomes. Routine
hrombectomy, distal protection, and possibly even a local
ntracoronary infusion of small doses of a thrombolytic
herapy might be considered approaches that could be
rospectively evaluated in randomized trials.
By contrast, the increased mortality and less ST-segment
esolution and so forth seen with persistent TIMI flow
rade 0 AWI could be a consequence of the later time to
eperfusion (a median of 40 min in this group) in compar-
son with those with baseline TIMI flow grade than
eopened AWI. The later the time to reperfusion, the more
ikely that the thrombus will be organized and/or there will
e greater microvascular damage (11). In this case, the
nding of persistent TIMI flow grade 0, which in this study,
as more likely to be the case in patients whose symptoms
egan at least 3 h before PCI, would be more of an
ssociation rather than responsible for the end point and a
herapeutic trial targeting thrombus, as mentioned, may not
e as effective (3). A combination of both processes (larger
hrombus burden and later reperfusion) could be responsible
n other cases.
Whether or not this study satisfies the 3 questions
nitially proposed, this finding was derived retrospectively
nd as such is more hypothesis-generating. Procedural
ariables other than the use of primary stenting and post-
tenting dilation are lacking. The adequacy of stent deploy-
ent and the type of stent (bare-metal vs. drug-eluting),
ifferences in anticoagulant regimens, use of intracoronary
asodilators, how and when thrombectomy was used, and
ho received post-discharge medicines and at what dose are
ust a few of the potential cofounders that could be respon-
ible for the worse outcome in those with persistent TIMIow grade 0 AWI. Even the type of wire (hydrophilic or
ncoated) might also have played a role in whether throm-
us embolized downstream or whether just a channel within
he thrombus was created leading to TIMI flow grade 0
WI.
Based on the deficiencies of this analysis, is it then
easonable to pursue further study? Given the potential
enefits of reducing mortality, we think the answer is yes.
uture trials that are appropriately sized should consider
hese and other potential confounders. Several end points
ncluding noninvasive determinants of infarct size, myocar-
ial blush scores, ST-segment resolution as well as cardio-
ascular (3) mortality should be assessed and different
herapeutic maneuvers including routine thrombectomy and
istal protection and so forth should be tested prospectively.
espite the limitations in this study, the investigators
hould be congratulated on their analysis. Their provocative
nd potentially important findings should generate further
tudy that may ultimately improve patient care.
eprint requests and correspondence: Dr. John A. Ambrose,
hief of Cardiology, UCSF Fresno, 2823 Fresno Street, 5th Floor,
resno, California 93721. E-mail: jamambrose@yahoo.com or
ambrose@fresno.ucsf.edu.
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